All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MDS Hub

MDS Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2019-06-19T09:34:29.000Z

EHA 2019 | AUGMENT study: Post-hoc analysis in MZL

By Emily Smith, Catherine Thieblemont
Featured
Catherine Thieblemont
Jun 19, 2019
Share:

Bookmark this article

At the 24th Congress of the European Hematology Association (EHA), Catherine Thieblemont from the Hôpital Saint-Louis, Paris, FR, shares a post-hoc analysis from the AUGMENT study in marginal zone lymphoma (MZL).

The AUGMENT study was a randomized study in patients with relapsed/refractory follicular lymphoma (FL) or MZL (20% of patients, n = 63). Patients were randomized to either R2 (rituximab and lenalidomide) or rituximab and placebo. The primary endpoint was progression-free survival (PFS).
 
At baseline, patients in the R2 arm had bulkier disease and there were significant differences in these baseline characteristics between the two arms. However, in the R2 arm, there was a higher overall response rate (65%) compared to rituximab and placebo (43%). This did not translate to differences in PFS.

AUGMENT study: Post-hoc analysis in MZL

More about...
AUGMENTEHA 2019Indolent B-cell lymphomasLenalidomideMarginal zone lymphomaRituximab

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

Which treatment do you select for patients with follicular lymphoma after multiple relapses?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox